Evidence map›Paper›PMID 39096379›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Pharmacodynamic, pharmacokinetic and rat brain receptor occupancy profile of NLX-112, a highly selective 5-HT

Ronan Y Depoortère, Andrew C McCreary, Benjamin Vidal, Mark A Varney, Luc Zimmer, Adrian Newman-Tancredi

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ronan Y DepoortèreNeurolixis SAS, 2 Rue Georges Charpak, 81100, Castres, France.
Andrew C McCrearyBrains On-Line, Groningen, Netherlands.
Benjamin VidalUniversité Claude Bernard Lyon 1, Lyon Neuroscience Research Center, CNRS, INSERM, CERMEP-Imaging Platform, Bron, France.
Mark A VarneyNeurolixis SAS, 2 Rue Georges Charpak, 81100, Castres, France.
Luc ZimmerUniversité Claude Bernard Lyon 1, Lyon Neuroscience Research Center, CNRS, INSERM, CERMEP-Imaging Platform, Bron, France.
Adrian Newman-TancrediNeurolixis SAS, 2 Rue Georges Charpak, 81100, Castres, France. anewmantancredi@neurolixis.com.

Funding

Agence Nationale de la Recherche ANR-11-IDEX-0007Michael J. Fox Foundation for Parkinson's Research Grant #9233Université Claude Bernard Lyon 1 ANR-11-LABX-0063
6 · The paper itself

Abstract

NLX-112 (i.e., F13640, befiradol) exhibits nanomolar affinity, exceptional selectivity and full agonist efficacy at serotonin 5-HT

Indexed as

BrainPyridinesReceptor, Serotonin, 5-HT1ASerotonin 5-HT1 Receptor AgonistsAnimalsAntiparkinson AgentsLevodopaMalePiperazinesPiperidinesRatsRats, Sprague-DawleyAntiparkinson AgentsbefiradolLevodopaPiperazinesPiperidinesPyridinesReceptor, Serotonin, 5-HT1ASerotonin 5-HT1 Receptor Agonists5-HT1A receptorsDyskinesiaL-DOPANLX-112Parkison’s diseasePharmacokineticsRat

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.